GABA levels in the brain: A target for new antiepileptic drugs

Neuroscientist

Volumn 2, Issue 6, 1996, Pages 326-334

  Kocsis, Jeffery D ^a   Mattson, Richard H ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Gabapentin; Nipecotic acid; Vigabatrin

Indexed keywords

EID: 3042929879     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849600200610     Document Type: Review

References (75)

1. Dichter MA, Ayala GF. Cellular mechanisms of epilepsy: a status report. Science 1987;237:157-164.
2. McNamara JO. Cellular and molecular basis of epilepsy. J Neurosci 1994;14:3413-3425.
3. Schwartz J, Vogel W. Diphenylhydantoin excitability reducing action in single myelinated nerve fibers. Eur J Pharmacol 1977;44: 241-249.
4. Courtney KR, Etter EF. Modulated anticonvulsant block of sodium channels in nerve and muscle. Eur J Pharmacol 1983;88:1-9.
5. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. In: Delgado-Escueta AV, Ward JR, Woodbury DM, Porter RJ, editors. Advances in neurology. New York: Raven Press 1986;713-736.
6. A receptor channels. In: Tunnicliff G, Raess BU, editors. GABA mechanisms in epilepsy. New York: Wiley-Liss 1991;89-104.
7. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem 1977;74:411-445.
8. Perry TL, Kish SJ, Hansen S. γ-vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain. J Neurochem 1979;32:1641-1645.
9. Gram L, Larsson OM, Johnsen A. Experimental studies of the influence of vigabatrin on the GABA system. Br Clin Pharmacol 1989;27:13S-17S.
10. Bolton JB, Rimmer E, Williams J, Richens A. The effect of vigabatrin on brain and platelet GABA-transminase activities. Br J Clin Pharmacol 1989;27:35S-42S.
11. Preece NE, Jackson GD, Houseman JA, Duncan JS, William SR. Nuclear magnetic resonance detection of increased cortical GABA in vigabatrin-treated rats in vivo. Epilepsia 1994;35:431-436.
12. Rimvall K, Martin DL. The level of GAD67 protein is highly sensitive to small increases in intraneuronal γ-aminobutyric acid levels. J Neurochem 1994; 62:1375-1381.
13. Browne TR, Mattson RH, Penry JK. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:184-189.
14. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services 1993;41-46.
15. Dreifuss FE. Gamma vinyl GABA (Vigabatrin) in epilepsy: the international experience. Epilepsia 1989;30(3 Suppl):S1-S5..
16. Lewis PJ, Richens A. Vigabatrin: a new anti-epileptic. Br J Clin Pharmacol 1989;27(1 Suppl):1S-129S.
17. Loescher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989;501:198-203.
18. Fariello R, Smith MC. Valproate: mechanisms of action. In: Mattson R, Meldrum B, Penry JK, Dreifuss FE, editors. Antiepileptic drugs. 3rd ed.. New York: Raven Press 1989;567-575.
19. Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994;169: 181-184.
20. Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995;692:273-277.
21. Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 1995;20:193-202.
22. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press 1995;829-841.
23. Roberts E, Frankel S. γ-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem 1950;187:55-63.
24. Awapara J, Landua AJ, Fuerst R, Seale B. Free γ-aminobutyric acid in brain. J Biol Chem 1950;187:35-39.
25. Florey E, McLennan H. The release of an inhibitory substance from mammalian brain, and its effect on peripheral synaptic transmission. J Physiol (Lond) 1955;129:384-392.
26. Elliott KAC, van Gelder NM. Occlusion and metabolism of γ-aminobutyric acid by brain tissue. J Neurochem 1958;3:28-40.
27. Bleck Th P, Klawans HL. Convulsive disorders: mechanisms of epilepsy and anticonvulsant action. Clin Neuropharmacol 1990; 13:121-128.
28. Kroogsgard-Larsen P, Falch E, Larsson OM, Schousboe A. GABA uptake inhibitors: Relevance to antiepileptic drug research. Epilepsy Res 1987;1:77-93.
29. B receptors in mammalian brain: Potential targets for drug development. Drug Dev Res 1990;61-166.
30. Ribak CE, Vaughn JE, Roberts E. The GABA neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry. J Comp Neurol 1979;187:261-284.
31. B receptors. In: Squires RF, editor. GABA and benzodiazepine receptors. Vol. 1. Boca Raton, FL: CRC Press 1988;107-121.
32. Krnjevic K. GABAergic inhibition in the neocortex. J Mind Behavior 1987;8:537-548.
33. B receptors and their significance in mammalian pharmacology. Trends Pharmacol Sci 1989;10:401-407.
34. Newbury NR, Nicoll RA. A biculline-resistant inhibitory post-synaptic potential in rat hippocampal pyramidal cells in vitro. J Physiol (Lond) 1984;348:239-254.
35. B receptors in the central nervous system. Nature (Lond) 1988;332:156-158.
36. Fyske EM, Fonnum F. Uptake of gamma-aminobutyric acid by a synaptic vesicle fraction isolated from rat brain. J Neurochem 1988;50:1237-1242.
37. Hell JW, Maycox PR, Stadler H, Jahn R. Uptake of GABA by rat brain synaptic vesicles isolated by a new procedure. EMBO J 1988;7:3023-3029.
38. Wood JD, Sidhu HS. Uptake of gamma-aminobutyric acid by brain tissue preparations: a re-evaluation. J Neurochem 1986;46: 739-744.
39. Pin J-P, Bockaert J. Two distinct mechanisms, differentially affected by excitatory amino acids, trigger GABA release from fetal mouse striatal neurons in primary culture. J Neurosci 1988;9:648-656.
40. Ostergaard LH, Gram L, Dam M. Potential antiepileptic drugs: Tiagabine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press 1995;1057-1061.
41. Fink-Jensen A, Suzdak PD, Swedberg MDB, Judge ME, Hansen L, Nielsen PG. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
42. During MJ, Mattson RH, Scheyer R. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus. Epilepsia 1992;33:83.
43. Yunger LM, Fowler PJ, Zarevics P, Setler PE. Novel inhibitors of gamma aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. J Pharmacol Exp Ther 1984;228:109-115.
44. Ali FE, Bondinell WE, Dandridge PA, et al. Orally active and potent inhibitors of γ-aminobutyric acid uptake. J Med Chem 1985;28:653-660.
45. Braestrup C, Nielsen EB, Wolffbrandt KH, Andersen KK, Knutsen LJS, Sonnewald U. Modulation of GABA receptor interactions with GABA uptake inhibitors. Int Congr Ser Excerpta Med 1987;750:125-128.
46. -966: potential role of GABA as a mediator in the pathogenesis of schizophrenia and mania. Drug Dev Res 1990;235-242.
47. Kocsis JD, Malenka RC, Waxman SG. Effects of extracellular potassium concentration on the excitability of the parallel fibres of the rat cerebellum. J Physiol (Lond) 1983;334:225-244.
48. 3H]GABA release from striatal slices: evidence for a calcium-independent process via the GABA uptake system. Neuroscience 1988;27:563-570.
49. Johnston GA, Stephanson AL, Twitchin B. Uptake and release of nipecotic acid by rat brain slices. J Neurochem 1976;26:83-87.
50. Moscowitz JA, Cutler RW. Bidirectional movement of gamma-aminobutyric acid in rat spinal cord slices. J Neurochem 1980;35: 1394-1399.
51. Szerb JC. Effect of nipecotic acid, a gamma-aminobutyric acid transport inhibitor, on the turnover and release of gamma-aminobutyric acid in rat cortical slices. J Neurochem 1982;39:850-858.
52. Ben-Menachem E, Persson LI, Mumford JP. Effect of long term vigabatrin therapy on selected CSF neurotransmitter concentrations. J Child Neurol 1991;6:11-16.
53. Ben-Menachem E, Persson L, Schlechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA homocamosine, homovanillic acid, 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101.
54. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 1995;36:457-464.
55. Mattson R. Managing epilepsy: the role of gabapentin. Neurology 1994;44(5 Suppl):S6.
56. Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994;44:S23-S30.
57. Sivenius J, Ylinen A, Murros K, Mumford JP, Riekkinen PJ. Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study. Neurology 1991;41:562-565.
58. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-1117.
59. US Gabapentin Study Group. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
60. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
61. Jung MJ, Lippert B, Metcalf BW, Schechter PJ, Bohlen P, Sjorerdsma A. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:787-802.
62. Schecter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989;27:195-225.
63. Schechter PJ, Hanke NF, Grove J, et al. Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 1984;34:182-186.
64. Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993;16:89-98.
65. Taylor CP, Vartanian MG, Andruszkiewicz R, et al. 3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res 1992;11:103-110.
66. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994;44:S10-S16.
67. Taylor CP. Mechanism of action of new anti-epileptic drugs. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services 1993; 13-40.
68. 3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993;244:303-309.
69. 3H]-gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur Pharmacol 1993;244:293-301.
70. 3H]gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur J Pharmacol 1993;247:341-345.
71. A receptors in developing rat optic nerve. Proc R Soc Lond B Biol Sci 1992; 247:155-161.
72. Lim JY, Utzschneider D, Sakatani K, Kocsis JD. The attenuation of GABA sensitivity in the maturing myelin-deficient rat optic nerve. Dev Brain Res 1993;72:15-29.
73. Ochi S, Lim JY, Rand MN, During MJ, Sakatani K, Kocsis JD. Transient presence of GABA in astrocytes of the developing optic nerve. Glia 1993;9:188-198.
74. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 1995;39:95-99.
75. Mattson RH, Petroff OAC, Rothman D, Behar K. Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol Scand 1995;162:27-30.